Clinical Trials
157 trialsNCT06376292 2026-05-18
A Prospective Single Arm Phase II Exploratory Study on the Combination of Whole Brain Radiotherapy, Thiotepa Intrathecal Injection and Systemic Treatment of Primary Diseases in the Treatment of Solid Tumor Leptomeningeal Metastasis
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Completed
NCT02399371 2026-05-08
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Phase 2 Completed
NCT04083976 2026-05-04
RAGNAR
Janssen Research & Development, LLC
Phase 2 Completed
NCT04886271 2026-04-15
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 2 Completed
NCT04911907 2026-04-03
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Completed
NCT01761929 2026-03-06
5fr SBRT
University Health Network, Toronto
Phase 2 Completed
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT05661578 2026-02-09
SKYSCRAPER-11
Hoffmann-La Roche
Phase 2 Completed
NCT02662504 2026-02-05
MesoPDT
University Hospital, Lille
Phase 2 Completed
NCT05419375 2026-02-03
Screening Study for Participants With Malignant Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT04504942 2026-01-23
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
CytoDyn, Inc.
Phase 2 Completed
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT05388058 2026-01-16
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Mayo Clinic
Phase 2 Completed
NCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
NCT05014828 2025-08-24
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT00354393 2025-07-15
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
Phase 2 Completed
NCT02078700 2025-06-25
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
Phase 2 Completed
NCT01197885 2025-06-13
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT05455424 2025-05-15
NERO
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed
NCT04082572 2025-05-13
Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05963386 2025-03-28
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
The First Affiliated Hospital of Xiamen University
Phase 2 Completed
NCT04716634 2025-03-25
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT03560973 2025-03-13
RAMES
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT04177953 2025-02-06
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03477175 2025-01-07
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
Eisai Inc.
Phase 2 Completed
NCT02057380 2024-11-20
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Inc
Phase 2 Completed
NCT01265433 2024-10-09
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Phase 2 Completed
NCT05660616 2024-08-27
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
Phase 2 Completed
NCT03802123 2024-07-09
iCorrelate
ImaginAb, Inc.
Phase 2 Completed
NCT04480372 2024-07-01
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Swiss Cancer Institute
Phase 2 Completed
NCT03861156 2024-04-09
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
InventisBio Co., Ltd
Phase 2 Completed
NCT00445965 2024-04-04
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05041062 2024-01-03
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
Phase 2 Completed
NCT03274661 2023-10-19
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Baptist Health South Florida
Phase 2 Completed
NCT03253679 2023-10-17
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
National Cancer Institute (NCI)
Phase 2 Completed
NCT01827384 2023-09-29
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
National Cancer Institute (NCI)
Phase 2 Completed
NCT04521179 2023-09-21
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Completed
NCT04346381 2023-09-18
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT01486368 2023-08-04
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Phase 2 Completed
NCT02506517 2023-08-01
A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene
University Health Network, Toronto
Phase 2 Completed
NCT02899195 2023-07-05
PrE0505
PrECOG, LLC.
Phase 2 Completed
NCT00101283 2023-07-03
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05898451 2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2 Completed
NCT02426892 2023-04-18
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03616834 2023-03-22
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Effector Therapeutics
Phase 2 Completed
NCT04115111 2023-03-15
Diadem
Mario Negri Institute for Pharmacological Research
Phase 2 Completed